Uncanny how quickly Brad Loncar can wrap his head around a new biotech company and pipeline. Notice how he leads this wide-ranging conversation without any notes at all. Then a same-day edit + post. Impressive! And the interview was loads of fun too. I appreciate better now why

New therapeutic modalities shift the Overton window for what success rates can look like. CAR-T, siRNA/RNAi, and antibodies have better success rates than small molecules. Success rates at Ph. 1 -> 2; 44-70% Ph. 2 -> 3; 34-58% Ph. 3 -> NDA 66-68% Granted these are smaller n,

Breaking through intranasal biologics production barriers. Our CEO Brian Finrow presents "Keep It Simple Stupid" at the Hanson Wade Nasal Formulation Summit in Boston next week. Register: nasal-formulation-delivery.com April 1-3, 2024 | Boston, MA

According to JPMorgan, this is largest tax increase since Revenue Act of 1968. It’s bizarre Congress gifted President power to unilaterally levy tariffs (in International Emergency Economic Powers Act of 1977). Since he can veto a repeal, takes two-thirds majorities to stop him.

So true, Mr. Dragon

you can't spell "tariffs" without "FFS"

The way we develop new drugs is broken. The process costs too much, takes too long, and far too often it simply doesn't work. I sat down with five leaders in the field—from industry, VC, academia, and government—to hear their takes on how, and why, and what we can do about it.

There is an insane degree of crowding out in pharma research. Everyone and their mother seems to be focusing on the same small sample of available drug targets! Maybe it's no coincidence that the number of novel targets has fallen by two-thirds as returns have fallen off.

FDA has one such huge data repository, currently locked away and sitting idle. Perhaps easily unlockable albeit with some agency creativity—idea #4 in this piece by me and Sandeep Patel in STAT last week: x.com/finrow/status/…

o3 pro is very very good.

Had a conversation with someone outside of healthcare recently who was shocked by how long it takes to run clinical trials in the U.S (not to mention expensive). I tried to explain—it’s not just the science. It’s the infrastructure. Every site needs dozens of personnel, many of

.Ross Rheingans-Yoo🔸 doesn't ask easy questions—he asks the right ones. Honored to be an early guest on the new Development & Research interview series, where we dug deep on what makes drug development tick.